{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:28:05Z","timestamp":1793276885759,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Project of Hebei Provincial Health and Family Planning Commission Fund","award":["20220133"],"award-info":[{"award-number":["20220133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06987-1","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:12:24Z","timestamp":1776733944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expression and prognostic impact of CD73 in classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Beichen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caili","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoning","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"6987_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/ajcp7yltqpusdq5c","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang QP, Lu ZH, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C, Zheng J, Liu W, Li G, Chen J (2012) Distribution of lymphoid neoplasms in China: Analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol 138:429\u2013434. https:\/\/doi.org\/10.1309\/ajcp7yltqpusdq5c","journal-title":"Am J Clin Pathol"},{"key":"6987_CR2","doi-asserted-by":"publisher","first-page":"929012","DOI":"10.3389\/fonc.2022.929012","volume":"12","author":"YJ Zhang","year":"2022","unstructured":"Zhang YJ, Xing ZC, Mi L, Li Z, Zhu J, Wei T, Wu W (2022) Novel agents for relapsed and refractory classical hodgkin lymphoma: A review. Front Oncol 12:929012. https:\/\/doi.org\/10.3389\/fonc.2022.929012","journal-title":"Front Oncol"},{"key":"6987_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","volume":"20","author":"RT Hoppe","year":"2022","unstructured":"Hoppe RT, Advani RH, Ai WZ et al (2022) NCCN Guidelines\u00ae insights: Hodgkin lymphoma, version 2.2022. J Natl Compr Canc Netw 20:322\u2013334. https:\/\/doi.org\/10.6004\/jnccn.2022.0021","journal-title":"J Natl Compr Canc Netw"},{"key":"6987_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand P, Chen YB, Redd RA et al (2019) PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood 134:22\u201329. https:\/\/doi.org\/10.1182\/blood.2019000215","journal-title":"Blood"},{"key":"6987_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger MA, K\u00fcppers R (2021) Molecular biology of Hodgkin lymphoma. Leukemia 35:968\u2013981. https:\/\/doi.org\/10.1038\/s41375-021-01204-6","journal-title":"Leukemia"},{"key":"6987_CR6","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1200\/jco.2010.32.8401","volume":"29","author":"C Steidl","year":"2011","unstructured":"Steidl C, Connors JM, Gascoyne RD (2011) Molecular pathogenesis of Hodgkin\u2019s lymphoma: Increasing evidence of the importance of the microenvironment. J Clin Oncol 29:1812\u20131826. https:\/\/doi.org\/10.1200\/jco.2010.32.8401","journal-title":"J Clin Oncol"},{"issue":"10","key":"6987_CR7","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.3390\/ijms20102416","volume":"20","author":"D Aldinucci","year":"2019","unstructured":"Aldinucci D, Borghese C, Casagrande N (2019) Formation of the immunosuppressive microenvironment of classic hodgkin lymphoma and therapeutic approaches to counter it. Int J Mol Sci 20(10):2416. https:\/\/doi.org\/10.3390\/ijms20102416","journal-title":"Int J Mol Sci"},{"key":"6987_CR8","doi-asserted-by":"publisher","first-page":"1515250","DOI":"10.3389\/fonc.2025.1515250","volume":"15","author":"T Aoki","year":"2025","unstructured":"Aoki T, Wierzbicki K, Sun S, Steidl C, Giulino-Roth L (2025) Tumor-microenvironment and molecular biology of classic Hodgkin lymphoma in children, adolescents, and young adults. Front Oncol 15:1515250. https:\/\/doi.org\/10.3389\/fonc.2025.1515250","journal-title":"Front Oncol"},{"key":"6987_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.21147\/j.issn.1000-9604.2020.03.03","volume":"32","author":"NK Lin","year":"2020","unstructured":"Lin NK, Song YQ, Zhu J (2020) Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. Chin J Cancer Res 32:303\u2013318. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2020.03.03","journal-title":"Chin J Cancer Res"},{"key":"6987_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Pacher P, Vizi ES, Hask\u00f3 G (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med 19:355\u2013367. https:\/\/doi.org\/10.1016\/j.molmed.2013.03.005","journal-title":"Trends Mol Med"},{"key":"6987_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fphar.2018.00266","volume":"9","author":"S Menzel","year":"2018","unstructured":"Menzel S, Schwarz N, Haag F, Koch-Nolte F (2018) Nanobody-based biologics for modulating purinergic signaling in inflammation and immunity. Front Pharmacol 9:266. https:\/\/doi.org\/10.3389\/fphar.2018.00266","journal-title":"Front Pharmacol"},{"key":"6987_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1146\/annurev-immunol-051116-052406","volume":"37","author":"J Linden","year":"2019","unstructured":"Linden J, Koch Nolte F, Dahl G (2019) Purine release, metabolism, and signaling in the inflammatory response. Annu Rev Immunol 37:325\u2013347. https:\/\/doi.org\/10.1146\/annurev-immunol-051116-052406","journal-title":"Annu Rev Immunol"},{"key":"6987_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Blandizzi C, Pacher P, Hask\u00f3 G (2013) Immunity, inflammation and cancer: A leading role for adenosine. Nat Rev Cancer 13:842\u2013857. https:\/\/doi.org\/10.1038\/nrc3613","journal-title":"Nat Rev Cancer"},{"key":"6987_CR14","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1172\/jci45559","volume":"121","author":"L Wang","year":"2011","unstructured":"Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B (2011) CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 121:2371\u20132382. https:\/\/doi.org\/10.1172\/jci45559","journal-title":"J Clin Invest"},{"key":"6987_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J (2020) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol 17:611\u2013629. https:\/\/doi.org\/10.1038\/s41571-020-0382-2","journal-title":"Nat Rev Clin Oncol"},{"key":"6987_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.trecan.2016.01.003","volume":"2","author":"L Antonioli","year":"2016","unstructured":"Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Hask\u00f3 G (2016) Anti-CD73 in cancer immunotherapy: Awakening new opportunities. Trends Cancer 2:95\u2013109. https:\/\/doi.org\/10.1016\/j.trecan.2016.01.003","journal-title":"Trends Cancer"},{"key":"6987_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41419-020-2403-6","volume":"11","author":"ZJ Xu","year":"2020","unstructured":"Xu ZJ, Gu CC, Yao XX, Guo W, Wang H, Lin T, Li F, Chen D, Wu J, Ye G, Zhao L, Hu Y, Yu J, Shi J, Li G, Liu H (2020) CD73 promotes tumor metastasis by modulating RICS\/RhoA signaling and EMT in gastric cancer. Cell Death Dis 11:202. https:\/\/doi.org\/10.1038\/s41419-020-2403-6","journal-title":"Cell Death Dis"},{"key":"6987_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4161\/cbt.6.3.3762","volume":"6","author":"P Zhou","year":"2007","unstructured":"Zhou P, Zhi XL, Zhou TT, Chen S, Li X, Wang L, Yin L, Shao Z, Ou Z (2007) Overexpression of Ecto-5\u2019-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix. Cancer Biol Ther 6:426\u2013431. https:\/\/doi.org\/10.4161\/cbt.6.3.3762","journal-title":"Cancer Biol Ther"},{"key":"6987_CR19","doi-asserted-by":"publisher","first-page":"460654","DOI":"10.1155\/2014\/460654","volume":"2014","author":"ZW Gao","year":"2014","unstructured":"Gao ZW, Dong K, Zhang HZ (2014) The roles of CD73 in cancer. Biomed Res Int 2014:460654. https:\/\/doi.org\/10.1155\/2014\/460654","journal-title":"Biomed Res Int"},{"key":"6987_CR20","doi-asserted-by":"publisher","first-page":"e001689","DOI":"10.1136\/jitc-2020-001689","volume":"8","author":"R Turiello","year":"2020","unstructured":"Turiello R, Capone M, Giannarelli D et al (2020) Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. J Immunother Cancer 8:e001689. https:\/\/doi.org\/10.1136\/jitc-2020-001689","journal-title":"J Immunother Cancer"},{"key":"6987_CR21","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/jco.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A (2022) COAST: An open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage iii non-small-cell lung cancer. J Clin Oncol 40:3383\u20133393. https:\/\/doi.org\/10.1200\/jco.22.00227","journal-title":"J Clin Oncol"},{"key":"6987_CR22","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"6987_CR23","volume-title":"Cancer. Principles and Practice of Oncology","author":"VT DeVita","year":"2001","unstructured":"DeVita VT, Hellman S, Rosenberg AS (2001) Cancer. Principles and Practice of Oncology, 6th edn. Lippincott Williams & Wilkins, Ed. Philadelphia","edition":"6"},{"key":"6987_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"6987_CR25","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138\u2013140. https:\/\/pubmed.ncbi.nlm.nih.gov\/3303008\/","journal-title":"Pathologe"},{"key":"6987_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12885-018-4073-7","volume":"18","author":"T Jiang","year":"2018","unstructured":"Jiang T, Xu XF, Qiao M, Li X, Zhao C, Zhou F, Gao G, Wu F, Chen X, Su C, Ren S, Zhai C, Zhou C (2018) Comprehensive evaluation of NT5E\/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer 18:267. https:\/\/doi.org\/10.1186\/s12885-018-4073-7","journal-title":"BMC Cancer"},{"key":"6987_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/pai.0b013e3182311d82","volume":"20","author":"A Supernat","year":"2012","unstructured":"Supernat A, Markiewicz A, Welnicka Jaskiewicz M, Seroczynska B, Skokowski J, Sejda A, Szade J, Czapiewski P, Biernat W, Zaczek A (2012) CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl Immunohistochem Mol Morphol 20:103\u2013107. https:\/\/doi.org\/10.1097\/pai.0b013e3182311d82","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"6987_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3802\/jgo.2012.23.4.274","volume":"23","author":"HK Oh","year":"2012","unstructured":"Oh HK, Sin JI, Choi J, Park SH, Lee TS, Choi YS (2012) Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J Gynecol Oncol 23:274\u2013281. https:\/\/doi.org\/10.3802\/jgo.2012.23.4.274","journal-title":"J Gynecol Oncol"},{"key":"6987_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/1078-0432.Ccr-15-1181","volume":"22","author":"BG Leclerc","year":"2016","unstructured":"Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J (2016) CD73 expression is an independent prognostic factor in prostate cancer. Clin Cancer Res 22:158\u2013166. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1181","journal-title":"Clin Cancer Res"},{"key":"6987_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1172\/jci79380","volume":"126","author":"JL Bowser","year":"2016","unstructured":"Bowser JL, Blackburn MR, Shipley GL, Molina JG, Dunner K Jr., Broaddus RR (2016) Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. J Clin Invest 126:220\u2013238. https:\/\/doi.org\/10.1172\/jci79380","journal-title":"J Clin Invest"},{"key":"6987_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-019-0728-3","volume":"12","author":"YX Kong","year":"2019","unstructured":"Kong YX, Jia B, Zhao CC, Claxton DF, Sharma A, Annageldiyev C, Fotos JS, Zeng H, Paulson RF, Prabhu KS, Zheng H (2019) Downregulation of CD73 associates with T cell exhaustion in AML patients. J Hematol Oncol 12:40. https:\/\/doi.org\/10.1186\/s13045-019-0728-3","journal-title":"J Hematol Oncol"},{"key":"6987_CR32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1084\/jem.182.5.1603","volume":"182","author":"L Airas","year":"1995","unstructured":"Airas L, Hellman J, Salmi M, Bono P, Puurunen T, Smith DJ, Jalkanen S (1995) CD73 is involved in lymphocyte binding to the endothelium: Characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. J Exp Med 182:1603\u20131608. https:\/\/doi.org\/10.1084\/jem.182.5.1603","journal-title":"J Exp Med"},{"key":"6987_CR33","doi-asserted-by":"publisher","first-page":"24888","DOI":"10.1074\/jbc.M300779200","volume":"278","author":"T Henttinen","year":"2003","unstructured":"Henttinen T, Jalkanen S, Yegutkin GG (2003) Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by Ecto-5\u2019-nucleotidase\/CD73-dependent mechanism. J Biol Chem 278:24888\u201324895. https:\/\/doi.org\/10.1074\/jbc.M300779200","journal-title":"J Biol Chem"},{"key":"6987_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450\u2013461. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001","journal-title":"Cancer Cell"},{"key":"6987_CR35","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/jco.2017.77.3994","volume":"36","author":"MGM Roemer","year":"2018","unstructured":"Roemer MGM, Redd RA, Cader FZ et al (2018) Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J Clin Oncol 36:942\u2013950. https:\/\/doi.org\/10.1200\/jco.2017.77.3994","journal-title":"J Clin Oncol"},{"key":"6987_CR36","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","volume":"125","author":"J Reichel","year":"2015","unstructured":"Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y, Gaiolla R, Eng K, Brody J, Inghirami G, Carlo-Stella C, Santoro A, Rahal D, Totonchy J, Elemento O, Cesarman E, Roshal M (2015) Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125:1061\u20131072. https:\/\/doi.org\/10.1182\/blood-2014-11-610436","journal-title":"Blood"},{"key":"6987_CR37","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cancers14051360","volume":"14","author":"V Men\u00e9ndez","year":"2022","unstructured":"Men\u00e9ndez V, Sol\u00f3rzano JL, Fern\u00e1ndez S, Montalb\u00e1n C, Garc\u00eda JF (2022) The hodgkin lymphoma immune microenvironment: Turning bad news into good. Cancers 14:1360. https:\/\/doi.org\/10.3390\/cancers14051360","journal-title":"Cancers"},{"key":"6987_CR38","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/bjh.18762","volume":"201","author":"J Grund","year":"2023","unstructured":"Grund J, Iben K, Reinke S, B\u00fchnen I, Pl\u00fctschow A, M\u00fcller-Meinhard B, Garcia Marquez MA, Schl\u00f6\u00dfer HA, von Tresckow B, Kellermeier F, Borchmann P, Engert A, Br\u00f6ckelmann PJ, Klapper W (2023) Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma. Br J Haematol 201:1097\u20131102. https:\/\/doi.org\/10.1111\/bjh.18762","journal-title":"Br J Haematol"},{"key":"6987_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2013-02-482406","volume":"122","author":"Z Saze","year":"2013","unstructured":"Saze Z, Schuler PJ, Hong CS, Cheng D, Jackson EK, Whiteside TL (2013) Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 122:9\u201318. https:\/\/doi.org\/10.1182\/blood-2013-02-482406","journal-title":"Blood"},{"issue":"21","key":"6987_CR40","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.3390\/ijms20215503","volume":"20","author":"E Calabretta","year":"2019","unstructured":"Calabretta E, d\u2019Amore F, Carlo-Stella C (2019) Immune and inflammatory cells of the tumor microenvironment represent novel therapeutic targets in classical hodgkin lymphoma. Int J Mol Sci 20(21):5503. https:\/\/doi.org\/10.3390\/ijms20215503","journal-title":"Int J Mol Sci"},{"key":"6987_CR41","doi-asserted-by":"publisher","first-page":"e004043","DOI":"10.1136\/jitc-2021-004043","volume":"10","author":"R Turiello","year":"2022","unstructured":"Turiello R, Capone M, Morretta E, Monti MC, Madonna G, Azzaro R, Del Gaudio P, Simeone E, Sorrentino A, Ascierto PA, Morello S (2022) Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. J Immunother Cancer 10:e004043. https:\/\/doi.org\/10.1136\/jitc-2021-004043","journal-title":"J Immunother Cancer"},{"key":"6987_CR42","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1158\/0008-5472.Can-17-0395","volume":"77","author":"J Reinhardt","year":"2017","unstructured":"Reinhardt J, Landsberg J, Schmid-Burgk JL et al (2017) MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res 77:4697\u20134709. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0395","journal-title":"Cancer Res"},{"key":"6987_CR43","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N et al (2022) Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study. Br J Haematol 198:847\u2013860. https:\/\/doi.org\/10.1111\/bjh.18348","journal-title":"Br J Haematol"},{"key":"6987_CR44","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/bloodadvances.2019000123","volume":"3","author":"M Picardi","year":"2019","unstructured":"Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F, Rascato MG, Cappuccio I, Raimondo M, Memoli M, Monteverde M, Mascolo M, Pane F (2019) Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv 3:1546\u20131552. https:\/\/doi.org\/10.1182\/bloodadvances.2019000123","journal-title":"Blood Adv"},{"key":"6987_CR45","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","volume":"106","author":"MJ Kersten","year":"2021","unstructured":"Kersten MJ, Driessen J, Zijlstra JM et al (2021) Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: The phase II HOVON\/LLPC Transplant BRaVE study. Haematologica 106:1129\u20131137. https:\/\/doi.org\/10.3324\/haematol.2019.243238","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06987-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:22:23Z","timestamp":1778750543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06987-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6987"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06987-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the International Ethical Guidelines for Biomedical Research Involving Human subjects and the 1964 Helsinki Declaration and its later amendments. The study was approved by the Ethics Committee of The Fourth Hospital of Hebei Medical University (protocol code: 2022KY191, date of approval: March 21, 2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"All participants provided written informed consent before being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}